Reviewing Sophiris Bio Inc. (SPHS)’s and Pfenex Inc. (NYSEAMERICAN:PFNX)’s results

Sophiris Bio Inc. (NASDAQ:SPHS) and Pfenex Inc. (NYSEAMERICAN:PFNX), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sophiris Bio Inc. N/A 0.00 16.26M -0.54 0.00
Pfenex Inc. 29.41M 4.31 27.28M -0.99 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 demonstrates the return on assets, net margins and return on equity of Sophiris Bio Inc. and Pfenex Inc.

Net Margins Return on Equity Return on Assets
Sophiris Bio Inc. 0.00% -946.2% -76.5%
Pfenex Inc. -92.76% -43.7% -32.3%

Risk and Volatility

A 1.95 beta means Sophiris Bio Inc.’s volatility is 95.00% more than Standard and Poor’s 500’s volatility. Pfenex Inc.’s 188.00% more volatile than Standard and Poor’s 500 which is a result of the 2.88 beta.


4.2 and 4.2 are the respective Current Ratio and a Quick Ratio of Sophiris Bio Inc. Its rival Pfenex Inc.’s Current and Quick Ratios are 3.7 and 3.7 respectively. Sophiris Bio Inc. has a better chance of clearing its pay short and long-term debts than Pfenex Inc.

Institutional and Insider Ownership

The shares of both Sophiris Bio Inc. and Pfenex Inc. are owned by institutional investors at 7.5% and 84.4% respectively. Insiders held 0.75% of Sophiris Bio Inc. shares. Comparatively, 0.1% are Pfenex Inc.’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sophiris Bio Inc. 1.01% -6.51% -29.97% -45.97% 5.24% -11.45%
Pfenex Inc. -7.49% -15.08% -26.49% -32.81% 70.22% 43.98%

For the past year Sophiris Bio Inc. has -11.45% weaker performance while Pfenex Inc. has 43.98% stronger performance.


Pfenex Inc. beats Sophiris Bio Inc. on 5 of the 9 factors.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.